Tag: Anticoagulant therapy

Clexane is the brand name for enoxaparin, a low molecular weight heparin (LMWH) used to prevent and treat serious blood clots. It is often prescribed following surgery or for medical conditions that increase the risk of venous thromboembolism.

It's a fact that active, uncontrollable bleeding is a primary reason when would heparin be contraindicated, highlighting the inherent risks of this potent anticoagulant. Recognizing the specific patient conditions and medical histories that make heparin use unsafe is a cornerstone of responsible pharmacotherapy, safeguarding patients from severe, and potentially life-threatening, hemorrhagic complications.

A 2012 pharmacy bulletin from UKM Medical Centre explicitly stated that Clexane (enoxaparin) and Arixtra (fondaparinux) are different anticoagulants used for deep vein thrombosis prophylaxis. The question, 'Is Clexane fondaparinux?', highlights a common point of confusion among patients and healthcare professionals due to their similar clinical roles.

In one clinical study, almost 99% of adults taking Xarelto® did not have another DVT or PE after 6 months of initial treatment [1.2.1]. So, what are the odds of getting a blood clot on Xarelto for the small percentage who do?

In a reported case study, a patient's blood clotting time (INR) significantly dropped after they began consuming one-half to one gallon of green tea daily. For those on anticoagulant therapy, it's crucial to understand how beverages like green tea affect the effectiveness of warfarin.